Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. (NASDAQ: JAGX) news covers a commercial-stage pharmaceuticals company focused on plant-based prescription medicines for gastrointestinal distress in humans and animals. The company’s updates frequently highlight progress across its crofelemer programs, regulatory interactions, and partnerships.
Investors following JAGX news can expect coverage of developments related to Mytesi, Napo Pharmaceuticals’ FDA-approved crofelemer product for noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, as well as Jaguar’s broader intestinal failure program targeting rare disorders such as short bowel syndrome with intestinal failure (SBS-IF) and microvillus inclusion disease (MVID). News items often describe clinical trial milestones, proof-of-concept data on reductions in parenteral support, and discussions with regulators about potential expedited approval pathways for ultrarare pediatric indications.
On the animal health side, Jaguar news includes information about Canalevia-CA1, the company’s conditionally approved crofelemer-based prescription drug for chemotherapy-induced diarrhea in dogs, along with regulatory grants, conditional approval renewals, and studies designed to support full approval. Updates may also address efforts to obtain guidance from the European Medicines Agency for Canalevia in general diarrhea in dogs.
Corporate and capital markets announcements are another key component of JAGX news. These can include securities purchase agreements, royalty interest amendments, PIPE financings, preferred stock exchanges, and at-the-market offering amendments, as disclosed in Form 8-K filings. Conference presentations, investor summit appearances, and summaries of stockholder meeting results also appear in the company’s news flow.
For investors and observers, the Jaguar Health news page provides a centralized view of clinical, regulatory, commercial, and financing developments that shape the company’s strategy in plant-based gastrointestinal therapeutics for both human and veterinary medicine.
Jaguar Health (NASDAQ:JAGX) announced plans to file its Q2 2020 10-Q on August 13, 2020. The company will host a conference call the same day at 8:30 a.m. ET to discuss financial results and updates. Investors can participate via a toll-free number or a live webcast on the company's website. Additionally, a virtual disease awareness event, Diarrhea Dialogues, is scheduled for October 20, 2020, focusing on cancer therapy-related diarrhea, featuring expert discussions on supportive care. Further details will be shared closer to the event date.
Jaguar Health, Inc. (NASDAQ:JAGX) will hold a conference call on August 13, 2020, at 8:30 a.m. ET to discuss Q2 2020 financials.
The company is also planning a virtual disease awareness event titled Diarrhea Dialogues on October 20, 2020, focusing on cancer therapy-related diarrhea, featuring leading oncologists and patient advocates. For more details on the investor call and event registration, visit the company's website.